Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Pancreatic Neoplasms 295Carcinoma, Non-Small-Cell Lung 160Lung Neoplasms 89Breast Neoplasms 84Urinary Bladder Neoplasms 83Cholangiocarcinoma 58Neoplasms 53Neoplasm Metastasis 51Ovarian Neoplasms 45Biliary Tract Neoplasms 45Lymphoma, Large B-Cell, Diffuse 32Lymphoma 30Sarcoma 29Hodgkin Disease 28Recurrence 26Nasopharyngeal Carcinoma 26Gallbladder Neoplasms 26Carcinoma, Transitional Cell 26Adenocarcinoma 22Triple Negative Breast Neoplasms 20Fallopian Tube Neoplasms 20Bile Duct Neoplasms 20Adenocarcinoma of Lung 20Carcinoma, Renal Cell 17Carcinoma, Ovarian Epithelial 16Urethral Neoplasms 15Lymphoma, Non-Hodgkin 15Colorectal Neoplasms 14Leiomyosarcoma 13Kidney Neoplasms 13

Interventions

Temozolomide 10Cyclophosphamide 10Vincristine 9Etoposide 6Doxorubicin 6Irinotecan 5palbociclib 4cabozantinib 4Topotecan 4Melphalan 4Magnetic Resonance Spectroscopy 4X-Rays 3Sirolimus 3Phantoms, Imaging 3Ifosfamide 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2ganitumab 2cixutumumab 2Vemurafenib 2Trabectedin 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Ewing × Gemcitabine × Clear all
NCT02945800 2026-04-02

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
59 enrolled 11 charts
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT05275426 2025-08-15

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
14 enrolled
Sarcoma

Sarcoma, Ewing

NCT02511132 2022-12-22

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Gradalis, Inc.

Phase 2 Completed
22 enrolled 13 charts
Sarcoma

Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡